EA201792328A1 - Способ очистки белков - Google Patents

Способ очистки белков

Info

Publication number
EA201792328A1
EA201792328A1 EA201792328A EA201792328A EA201792328A1 EA 201792328 A1 EA201792328 A1 EA 201792328A1 EA 201792328 A EA201792328 A EA 201792328A EA 201792328 A EA201792328 A EA 201792328A EA 201792328 A1 EA201792328 A1 EA 201792328A1
Authority
EA
Eurasian Patent Office
Prior art keywords
monomeric
antibody
domain
human
relates
Prior art date
Application number
EA201792328A
Other languages
English (en)
Inventor
Сэм Филип Хейвуд
Гэвин Бэрри Уайлд
Original Assignee
Юсб Биофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Биофарма Спрл filed Critical Юсб Биофарма Спрл
Publication of EA201792328A1 publication Critical patent/EA201792328A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к способу получения антитела, содержащего домен VH3 человека, в мономерной форме. Конкретно настоящее изобретение относится к новому способу, обеспечивающему получение мономерного антитела, содержащего домен VH3 человека, из смеси, содержащей мономерную и мультимерные формы антитела.
EA201792328A 2015-04-22 2016-04-20 Способ очистки белков EA201792328A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506868.7A GB201506868D0 (en) 2015-04-22 2015-04-22 Method for protein purification
PCT/EP2016/058774 WO2016169992A1 (en) 2015-04-22 2016-04-20 Method for protein purification

Publications (1)

Publication Number Publication Date
EA201792328A1 true EA201792328A1 (ru) 2018-05-31

Family

ID=53299017

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792328A EA201792328A1 (ru) 2015-04-22 2016-04-20 Способ очистки белков

Country Status (19)

Country Link
US (2) US10927164B2 (ru)
EP (1) EP3286205A1 (ru)
JP (2) JP6866300B2 (ru)
KR (1) KR102675400B1 (ru)
CN (1) CN107636012B (ru)
AR (1) AR104358A1 (ru)
AU (1) AU2016251223B2 (ru)
BR (1) BR112017022073A2 (ru)
CA (1) CA2983057A1 (ru)
CL (1) CL2017002614A1 (ru)
CO (1) CO2017010631A2 (ru)
EA (1) EA201792328A1 (ru)
GB (1) GB201506868D0 (ru)
IL (1) IL254883B (ru)
MA (1) MA41941A (ru)
MX (1) MX2017013333A (ru)
MY (1) MY189854A (ru)
SG (1) SG11201708256YA (ru)
WO (1) WO2016169992A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013081540A1 (en) * 2011-11-30 2013-06-06 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CN108085358A (zh) * 2018-02-08 2018-05-29 保定冀中药业有限公司 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法
EP4007771A1 (en) 2019-08-02 2022-06-08 UCB Biopharma SRL Methods for purifying antibodies
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
AU2020414489A1 (en) * 2019-12-26 2022-07-14 Abl Bio Inc. Method for purifying biologically active peptide by using protein a affinity chromatography
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
CA2374013A1 (en) 1999-05-15 2000-11-23 University Of California, San Diego Protein a based binding domains with desirable activities
WO2002059264A2 (en) * 2000-12-29 2002-08-01 Bio-Technology General Corp. Specific human antibodies for selective cancer therapy
US20060257972A1 (en) * 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
AU2009282234A1 (en) * 2008-08-14 2010-02-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
HUE042114T2 (hu) * 2009-02-17 2019-06-28 Ucb Biopharma Sprl Humán OX40-re specifikus ellenanyag-molekulák
EP2635599A1 (en) * 2010-11-01 2013-09-11 DSM IP Assets B.V. Single unit ion exchange chromatography antibody purification
US8859726B2 (en) 2010-11-29 2014-10-14 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
DK2776466T3 (da) 2011-11-11 2017-11-20 Ucb Biopharma Sprl Albuminbindende antistoffer og bindingsfragmenter deraf
BR112014019579A2 (pt) * 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
NZ720161A (en) * 2013-11-04 2022-07-29 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
MA41941A (fr) 2018-02-28
US20210171609A1 (en) 2021-06-10
SG11201708256YA (en) 2017-11-29
KR102675400B1 (ko) 2024-06-13
BR112017022073A2 (pt) 2018-08-14
MX2017013333A (es) 2018-02-19
JP2021066734A (ja) 2021-04-30
KR20170139131A (ko) 2017-12-18
US10927164B2 (en) 2021-02-23
IL254883B (en) 2021-09-30
AU2016251223A1 (en) 2017-10-26
CL2017002614A1 (es) 2018-04-27
IL254883A0 (en) 2017-12-31
EP3286205A1 (en) 2018-02-28
US20180100007A1 (en) 2018-04-12
JP6866300B2 (ja) 2021-04-28
CO2017010631A2 (es) 2018-01-05
AR104358A1 (es) 2017-07-12
AU2016251223B2 (en) 2021-12-09
CA2983057A1 (en) 2016-10-27
MY189854A (en) 2022-03-14
JP2018520089A (ja) 2018-07-26
CN107636012A (zh) 2018-01-26
WO2016169992A1 (en) 2016-10-27
CN107636012B (zh) 2022-08-02
GB201506868D0 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
EA201792328A1 (ru) Способ очистки белков
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201891992A1 (ru) Химерные рецепторы и способы их применения
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201592203A1 (ru) Способы лечения таупатии
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201691541A1 (ru) Новые анти-baff антитела